An expert in acquired TTP describes the use of caplacizumab in treating acquired TTP, and highlights data from a phase III clinical trial. X. Long Zheng, MD, PhD: Now we can talk about caplacizumab.

Caplacizumab is a von Willebrand factor (vWF)-directed antibody fragment designed to inhibit the interaction between vWF and platelets.

X. Long Zheng, MD, PhD, discusses the unmet needs of acquired TTP, and the future of treatment. X. Long Zheng, MD, PhD: What are the unmet needs in acquired TTP [thrombotic thrombocytopenic purpura] ...

Time to progression (TTP) is suggested as a reliable endpoint compared with the progression-free survival in the clinical trials of hepatocellular carcinoma (HCC). However, the correlation between TTP ...

License obtained from Kaketsuken is worldwide and exclusive except for Japan. Baxter International received a worldwide license to Kaketsuken’s drug candidate for the treatment of thrombotic ...

A rare autoimmune disease creates sudden pain in the abdomen or the head, sending a patient to the emergency room with a potentially fatal condition. The pain comes from a multitude of blockages of ...

cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms Takeda Continues 70-plus Year Legacy of Driving Innovation for the Rare ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted Takeda’s Biologics License Application (BLA) ...